Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by LithLoveron Feb 11, 2021 11:21am
153 Views
Post# 32537885

RE:RE:RE:DESPERATE BASHING

RE:RE:RE:DESPERATE BASHINGOk here's the dream. 

1) Tripp halts the stock and news comes out that an agreement has been made or letter of understanding from Blue Cross/Blue Shield that they have approved the test for their members. 

2) A week later Tripp halts and announces Aristotle is fully commercialized and avaiable to all

3) Tripp announces a national deal with numerous first responders/fire fighter associations to be tested

4) Tripp announces medicare/medicaid and others will fully fund the test 




NoGambleNoFutur wrote: I understand that many of us are waiting for SZLS to announce partnerships, but in my personal opinion, I think that's going to be the easiest point moving forward. When they release Aristotle, which is one of the first multi-cancer screening tests to become available on the market, I think they'll be able to close some valuable partnerships. I just want all of you to realize something quite important though. I feel like this industry in general can only be successful if employers include this type of testing in employee's benefits/insurance plans. Ask anyone around you, everyone would love to do this type of test, but the moment you mention that it's $300 USD, you're narrowing the amount of buyers by a substantial amount. If you found out that your insurance plan covers 90% of this test, everyone would be inclided to do it. I can't see this industry being extremely succesful unless it's covered by insurance. I'm obviously taking a gamble on the fact that it will in the future.


<< Previous
Bullboard Posts
Next >>